These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6336765)

  • 1. A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances.
    Yoshikawa M; Hirai S; Aizawa T; Kuroiwa Y; Goto F; Sofue I; Toyokura Y; Yamamura H; Iwasaki Y
    J Am Geriatr Soc; 1983 Jan; 31(1):1-7. PubMed ID: 6336765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.
    Misurec J; Morávek Z; Náhunek K; Cesková E; Sláma B; Svestka J
    Act Nerv Super (Praha); 1978 Dec; 20(4):266-7. PubMed ID: 367038
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
    Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
    Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled clinical study of use of dihydroergocristine in cerebral and periferal vascular disorders].
    Calisti G; Biscarini L; Miseo A
    Clin Ter; 1977 Nov; 83(4):371-86. PubMed ID: 414875
    [No Abstract]   [Full Text] [Related]  

  • 5. [Controlled double-blind study of the clinical equivalent of two posologic regimens of Hydergine: 1 x 4,5mg compared to 3 x 1,5mg per day].
    Piguet PV; Zoufal Z
    Rev Med Suisse Romande; 1981 Feb; 101(2):157-63. PubMed ID: 7015453
    [No Abstract]   [Full Text] [Related]  

  • 6. [Eutergin in the treatment of chronic cerebrovascular disturbance patterns (author's transl)].
    Prosenz P
    Aktuelle Gerontol; 1980 Jun; 10(6):245-51. PubMed ID: 6109460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of Ergocomb in symptoms of cerebrovascular insufficiency].
    Pöthig D; Sauer I; Hansen H; Weidnitzer M
    Z Alternsforsch; 1983; 38(6):443-9. PubMed ID: 6659572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of daily dosages of 6 mg and 20 mg dihydroergocristine in the treatment of chronic cerebro-vascular disease.
    Pagliano FM; Galbiati GC
    J Int Med Res; 1995; 23(4):219-27. PubMed ID: 7589764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report.
    Yesavage JA; Hollister LE; Burian E
    J Am Geriatr Soc; 1979 Feb; 27(2):80-2. PubMed ID: 762369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dihydroergotoxine mesylate in the treatment of senile cerebral insufficiency. Result of a long-term multicenter double-blind clinical trial with a placebo].
    Lazzari R; Passeri M; Chierichetti SM
    Presse Med; 1983 Dec; 12(48):3179-85. PubMed ID: 6228938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.
    Thienhaus OJ; Wheeler BG; Simon S; Zemlan FP; Hartford JT
    J Am Geriatr Soc; 1987 Mar; 35(3):219-23. PubMed ID: 3819261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled clinical trial of dihydroergocristine in neuropsychiatric disorders in cerebrovascular insufficiency].
    Muchnik S
    Boll Chim Farm; 1982 May; 121(5):33S-46S. PubMed ID: 6814466
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical evaluation of GABA in the treatment of cerebrovascular disorders. Multi-center double-blind study in comparison with pyrithioxine and placebo.
    Otomo E; Araki G; Mori A; Kurihara M
    Arzneimittelforschung; 1981; 31(9):1511-23. PubMed ID: 7030354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation.
    Setnikar I; Schmid K; Rovati LC; Vens-Cappell B; Mazur D; Kozak I
    Arzneimittelforschung; 2001 Jan; 51(1):2-6. PubMed ID: 11215321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term ergoloid mesylates ('Hydergine') administration in healthy pensioners: 5-year results.
    Huber F; Köberle S; Prestele H; Spiegel R
    Curr Med Res Opin; 1986; 10(4):256-79. PubMed ID: 3780290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind study of flunarizine versus placebo in patients with chronic cerebrovascular disorders.
    Agnoli A; Manna V; Martucci N; Fioravanti M; Ferromilone F; Cananzi A; D'Andrea G; De Rosa A; Vizioli R; Sinforiani E
    Int J Clin Pharmacol Res; 1988; 8(3):189-97. PubMed ID: 3042644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methodology of a controlled trial of dihydroergotoxine in acquired intellectual impairment in the adult].
    Dartigues JF; Père JJ
    Presse Med; 1983 Dec; 12(48):3173-5. PubMed ID: 6228936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of vasobral in patients with chronic cerebrovascular disorders].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):70-2. PubMed ID: 22500318
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dihydroergotoxine mesylate in chronic cerebrovascular insufficiency: spectral EEG analysis and neuropsychological correlates].
    Moglia A; Bono G; Sinforiani E; Alfonsi E; Zandrini C; Pistarini C; Arrigo A; Franch F
    Farmaco Prat; 1983 Feb; 38(2):97-102. PubMed ID: 6832350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.